Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 12/2012

01.11.2012 | Head and Neck Oncology

Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels

verfasst von: Shiang-Fu Huang, MD, PhD, Fu-Chan Wei, MD, Chun-Ta Liao, MD, Hung-Ming Wang, MD, Chien-Yu Lin, MD, Steven Lo, MD, Jung-Ju Huang, MD, I-How Chen, MD, Chung-Jan Kang, MD, Huei-Tzu Chien, MS, Hsuan-Ho Chen, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Squamous cell carcinoma antigen (SCC-Ag) level and C-reactive protein (CRP) have been shown to be associated with tumor invasion, lymph node metastasis, staging and survival in patients with oral squamous cell carcinoma (OSCC). The purpose of the present study was to analyze the relationship between preoperative levels of both SCC-Ag and CRP, with clinicopathologic factors and prognosis in OSCC patients.

Methods

A retrospective study was performed on 142 OSCC patients between March 2008 and March 2011. Their serum SCC-Ag and CRP levels were measured preoperatively.

Results

SCC-Ag level of ≥2.0 ng/ml and CRP level ≥5.0 mg/L were significantly associated with pathologic tumor status (P < 0.001), pathologic nodal metastasis (P = 0.001), tumor depth (≥10 mm vs. <10 mm, P < 0.001), disease-free survival (P ≤ 0.001) and overall survival (P ≤ 0.001). The influence of SCC-Ag and CRP level on disease-free survival (hazard ratio 4.046, 95 % confidence interval 1.698–9.692) and overall survival (hazard ratio 3.655, 95 % confidence interval 1.464–9.130) still existed after adjusting for tumor status, lymph node metastasis and tumor cell differentiation.

Conclusions

Concurrent high levels of both preoperative SCC-Ag and CRP levels act as a predictor for lymph node metastasis, advanced tumor stage and tumor recurrence. It therefore has significant potential as a biomarker for risk stratification in OSCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Liao CT, Wang HM, Ng SH, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42:800–9.PubMedCrossRef
3.
O’Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM. The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg. 2000;126:360–5.PubMed
4.
Lin WH, Chen IH, Wei FC, et al. Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma. Laryngoscope. 2011;121:971–7.PubMedCrossRef
5.
Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 2011;36:147–53.PubMedCrossRef
6.
Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:50–8.PubMedCrossRef
7.
Kato H, Tamai K, Morioka H, Nagai M, Nagaya T, Torigoe T. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer. 1984;54:1544–6.PubMedCrossRef
8.
Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21–1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000;89:1413–7.PubMedCrossRef
9.
Margolis ML, Hyzy JB, Schenken LL, Schepart BS. Serum tumor markers in non-small cell lung cancer. A comparative analysis. Cancer. 1994;73:605–9.PubMedCrossRef
10.
Pectasides D, Bafaloucos D, Antoniou F, et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19–9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 1996;19:271–7.PubMedCrossRef
11.
Petrelli NJ, Shaw N, Bhargava A, et al. Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J Clin Oncol. 1988;6:782–5.PubMed
12.
Eibling DE, Johnson JT, Wagner RL, Su S. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope. 1989;99:117–24.PubMedCrossRef
13.
Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–24.PubMedCrossRef
14.
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRef
15.
McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64–9.PubMed
16.
Suh SY, Ahn HY. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer. 2007;15:613–20.PubMedCrossRef
17.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRef
18.
19.
Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483–7.PubMedCrossRef
20.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, editors. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
21.
Huang SF, Kang CJ, Lin CY, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112:1066–75.PubMedCrossRef
22.
Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–22.PubMedCrossRef
23.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40:1621–8.PubMedCrossRef
24.
25.
Takeda A, Kajiya A, Iwasawa A, Nakamura Y, Hibino T. Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor–mediated apoptosis. Biol Chem. 2002;383:1231–6.PubMedCrossRef
26.
Sueoka K, Nawata S, Nakagawa T, et al. Tumor-associated serpin, squamous cell carcinoma antigen stimulates matrix metalloproteinase-9 production in cervical squamous cell carcinoma cell lines. Int J Oncol. 2005;27:1345–53.PubMed
27.
Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9.PubMedCrossRef
28.
Meier W, Eiermann W, Stieber P, Schneider A, Fateh-Moghadam A, Hepp H. Experiences with SCC antigen, a new tumor marker for cervical carcinoma. Eur J Cancer Clin Oncol. 1989;25:1555–9.PubMedCrossRef
29.
Neunteufel W, Tatra G, Bieglmayer C. Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls. Arch Gynecol Obstet. 1989;246:243–50.PubMedCrossRef
30.
Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol. 1990;37:260–3.PubMedCrossRef
31.
Scambia G, Panici PB, Baiocchi G, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol. 1991;164:631–6.PubMed
32.
Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol. 1987;157:433–9.PubMed
33.
Kimura Y, Fujieda S, Takabayashi T, Tanaka T, Sugimoto C, Saito H. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett. 2000;155:163–8.PubMedCrossRef
34.
Lachowicz MA, Hassmann-Poznanska E, Kozlowski MD, Rzewnicki I. Squamous cell carcinoma antigen in patients with cancer of the larynx. Clin Otolaryngol Allied Sci. 1999;24:270–3.PubMedCrossRef
35.
Lara PC, Cuyas JM. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer. 1995;76:758–64.PubMedCrossRef
36.
Molina R, Torres MD, Moragas M, et al. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol. 1996;17:81–9.PubMedCrossRef
37.
Yasumatsu R, Nakashima T, Azuma K, et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett. 2001;167:205–13.PubMedCrossRef
38.
Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg. 1998;26:243–8.PubMedCrossRef
39.
Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24.PubMedCrossRef
40.
Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.PubMed
41.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.PubMedCrossRef
42.
43.
McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.PubMedCrossRef
44.
Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568–71.PubMed
45.
Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.PubMedCrossRef
46.
Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women’s Heart and Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16:1155–9.PubMedCrossRef
47.
Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20:15–26.PubMedCrossRef
48.
McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127–9.PubMedCrossRef
49.
Gallo O, Gori AM, Attanasio M, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol. 1995;252:159–62.PubMedCrossRef
50.
Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1β, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res. 1997;3:126–9.PubMedCrossRef
51.
Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912–4.PubMedCrossRef
52.
Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2010;2:21.PubMedCrossRef
Metadaten
Titel
Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels
verfasst von
Shiang-Fu Huang, MD, PhD
Fu-Chan Wei, MD
Chun-Ta Liao, MD
Hung-Ming Wang, MD
Chien-Yu Lin, MD
Steven Lo, MD
Jung-Ju Huang, MD
I-How Chen, MD
Chung-Jan Kang, MD
Huei-Tzu Chien, MS
Hsuan-Ho Chen, MD
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2392-5

Weitere Artikel der Ausgabe 12/2012

Annals of Surgical Oncology 12/2012 Zur Ausgabe

Hepatobiliary Tumors

Treating Patients with Colon Cancer Liver Metastasis: A Nationwide Analysis of Therapeutic Decision Making

Healthcare Policy and Outcomes

Frequent and Early Death Limits Quality of Life Assessment in Patients with Advanced Malignancies Evaluated for Palliative Surgical Intervention

Colorectal Cancer

Evaluation of Lymphadenectomy in Patients Receiving Neoadjuvant Radiotherapy for Rectal Adenocarcinoma

Gynecologic Oncology

Systematic Para-aortic and Pelvic Lymphadenectomy in Early Stage Epithelial Ovarian Cancer: A Prospective Study

Breast Oncology

A Randomized, Controlled Trial Comparing Acetaminophen Plus Ibuprofen versus Acetaminophen Plus Codeine Plus Caffeine (Tylenol 3) after Outpatient Breast Surgery

Colorectal Cancer

Tumor Budding is an Independent Predictor of Outcome in AJCC/UICC Stage II Colorectal Cancer

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.